We are live on ! Find out more
SNDX icon

Syndax Pharmaceuticals
SNDX

45 hedge funds and large institutions have $176M invested in Syndax Pharmaceuticals in 2016 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 18 increasing their positions, 13 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more funds holding in top 10

Funds holding in top 10: 1 → 2 (+1)

73% more capital invested

Capital invested by funds: $102M → $176M (+$73.9M)

38% more repeat investments, than reductions

Existing positions increased: 18 | Existing positions reduced: 13

4% less funds holding

Funds holding: 47 → 45 (-2)

33% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 6

Holders
45
Holders Change
-2
Holders Change %
-4.26%
% of All Funds
1.2%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.05%
New
4
Increased
18
Reduced
13
Closed
6
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
Wellington Management Group
Wellington Management Group
Massachusetts
+$11.5M
2
ACH
ArrowMark Colorado Holdings
Colorado
+$3.88M
3
SFM
Sphera Funds Management
Israel
+$2.19M
4
Vanguard Group
Vanguard Group
Pennsylvania
+$1.62M
5
TAM
Tiverton Asset Management
Delaware
+$1.51M

Top Sellers

1
RG
Redmile Group
California
-$2.47M
2
Jennison Associates
Jennison Associates
New York
-$2.02M
3
Norges Bank
Norges Bank
Norway
-$244K
4
BIT
BlackRock Institutional Trust
California
-$224K
5
Millennium Management
Millennium Management
New York
-$137K
Name Holding Trade Value Shares
Change 		Change in
Stake
Wellington Management Group
1
Wellington Management Group
Massachusetts
$32.9M +$11.5M +877,647 +68%
MAM
2
MPM Asset Management
Massachusetts
$32.9M – – –
Fidelity Investments
3
Fidelity Investments
Massachusetts
$31.8M – – –
BA
4
BlackRock Advisors
Delaware
$15.6M -$14.9K -1,130 -0.1%
O
5
OrbiMed
New York
$11.5M – – –
ACH
6
ArrowMark Colorado Holdings
Colorado
$7.09M +$3.88M +294,828 +171%
Jennison Associates
7
Jennison Associates
New York
$5.82M -$2.02M -153,769 -29%
EC
8
EcoR1 Capital
California
$5.42M – – –
Vanguard Group
9
Vanguard Group
Pennsylvania
$4.44M +$1.62M +123,023 +72%
CAM
10
Cormorant Asset Management
Massachusetts
$3.65M +$342K +25,984 +12%
BC
11
Boxer Capital
California
$3.55M – – –
BG
12
BlackRock Group
United Kingdom
$2.67M -$35.5K -2,700 -2%
Alyeska Investment Group
13
Alyeska Investment Group
Illinois
$2.56M +$576K +43,772 +35%
SFM
14
Sphera Funds Management
Israel
$2.52M +$2.19M +166,310 New
BFA
15
BlackRock Fund Advisors
California
$1.98M +$88K +6,691 +5%
TAM
16
Tiverton Asset Management
Delaware
$1.87M +$1.51M +114,524 +1,330%
USAA
17
United Services Automobile Association
Texas
$1.35M +$431K +32,800 +58%
Geode Capital Management
18
Geode Capital Management
Massachusetts
$1.32M +$750K +57,056 +190%
State Street
19
State Street
Massachusetts
$840K +$129K +9,776 +21%
Northern Trust
20
Northern Trust
Illinois
$802K +$36K +2,736 +5%
GE
21
General Electric
Ohio
$726K -$75K -5,701 -11%
BlackRock
22
BlackRock
New York
$680K – – –
KCM
23
Kornitzer Capital Management
Kansas
$559K -$113K -8,600 -19%
BIM
24
BlackRock Investment Management
Delaware
$547K – – –
BIT
25
BlackRock Institutional Trust
California
$397K -$224K -17,050 -39%
1
2 3

SNDX Hedge Fund Activity: Q3 2016 in Review

45 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Syndax Pharmaceuticals (SNDX) for Q3 2016, worth a combined $176M — up 73% from $102M a quarter earlier.

Sellers outnumbered buyers: 6 funds closed out of SNDX and 4 opened new positions — a net loss of 2 holders — while 13 trimmed existing stakes and 18 added.

The largest buyer was Wellington Management Group, adding an estimated $11.5M. The largest seller was Redmile Group, exiting entirely with an estimated $2.47M sold.

  • 45 institutional investors held Syndax Pharmaceuticals (SNDX) as of Q3 2016, down from 47 in Q2 2016.
  • Funds reported $176M of Syndax Pharmaceuticals stock for Q3 2016, up 73% quarter-over-quarter.
  • 4 funds opened new Syndax Pharmaceuticals positions in Q3 2016 and 6 closed out, a net change of -2 holders.
  • The largest Syndax Pharmaceuticals buyer in Q3 2016 was Wellington Management Group, an estimated $11.5M added.
  • The largest Syndax Pharmaceuticals seller in Q3 2016 was Redmile Group, an estimated $2.47M sold.

Based on aggregated 13F filings for Q3 2016.